These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

561 related articles for article (PubMed ID: 22310591)

  • 1. Impact of cytochrome P450 3A and ATP-binding cassette subfamily B member 1 polymorphisms on tacrolimus dose-adjusted trough concentrations among Korean renal transplant recipients.
    Cho JH; Yoon YD; Park JY; Song EJ; Choi JY; Yoon SH; Park SH; Kim YL; Kim CD
    Transplant Proc; 2012 Jan; 44(1):109-14. PubMed ID: 22310591
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tacrolimus concentrations in relation to CYP3A and ABCB1 polymorphisms among solid organ transplant recipients in Korea.
    Jun KR; Lee W; Jang MS; Chun S; Song GW; Park KT; Lee SG; Han DJ; Kang C; Cho DY; Kim JQ; Min WK
    Transplantation; 2009 Apr; 87(8):1225-31. PubMed ID: 19384171
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influence of CYP3A5 and MDR1(ABCB1) polymorphisms on the pharmacokinetics of tacrolimus in Chinese renal transplant recipients.
    Rong G; Jing L; Deng-Qing L; Hong-Shan Z; Shai-Hong Z; Xin-Min N
    Transplant Proc; 2010 Nov; 42(9):3455-8. PubMed ID: 21094796
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ABCB1 polymorphisms are associated with cyclosporine-induced nephrotoxicity and gingival hyperplasia in renal transplant recipients.
    García M; Macías RM; Cubero JJ; Benítez J; Caravaca F; Gervasini G
    Eur J Clin Pharmacol; 2013 Mar; 69(3):385-93. PubMed ID: 22886152
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tacrolimus pharmacokinetics and pharmacogenetics: influence of adenosine triphosphate-binding cassette B1 (ABCB1) and cytochrome (CYP) 3A polymorphisms.
    Op den Buijsch RA; Christiaans MH; Stolk LM; de Vries JE; Cheung CY; Undre NA; van Hooff JP; van Dieijen-Visser MP; Bekers O
    Fundam Clin Pharmacol; 2007 Aug; 21(4):427-35. PubMed ID: 17635182
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical and genetic factors affecting tacrolimus trough levels and drug-related outcomes in Korean kidney transplant recipients.
    Kim IW; Moon YJ; Ji E; Kim KI; Han N; Kim SJ; Shin WG; Ha J; Yoon JH; Lee HS; Oh JM
    Eur J Clin Pharmacol; 2012 May; 68(5):657-69. PubMed ID: 22183771
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influence of CYP3A4, CYP3A5 and MDR-1 polymorphisms on tacrolimus pharmacokinetics and early renal dysfunction in liver transplant recipients.
    Shi Y; Li Y; Tang J; Zhang J; Zou Y; Cai B; Wang L
    Gene; 2013 Jan; 512(2):226-31. PubMed ID: 23107770
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of CYP3A5, CYP3A4, and ABCB1 genotypes as determinants of tacrolimus dose and clinical outcomes after heart transplantation.
    Díaz-Molina B; Tavira B; Lambert JL; Bernardo MJ; Alvarez V; Coto E
    Transplant Proc; 2012 Nov; 44(9):2635-8. PubMed ID: 23146479
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multidrug resistance-associated protein 2 (MRP2/ABCC2) haplotypes significantly affect the pharmacokinetics of tacrolimus in kidney transplant recipients.
    Ogasawara K; Chitnis SD; Gohh RY; Christians U; Akhlaghi F
    Clin Pharmacokinet; 2013 Sep; 52(9):751-62. PubMed ID: 23633119
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influence of ABCB1 polymorphisms and haplotypes on tacrolimus nephrotoxicity and dosage requirements in children with liver transplant.
    Hawwa AF; McKiernan PJ; Shields M; Millership JS; Collier PS; McElnay JC
    Br J Clin Pharmacol; 2009 Sep; 68(3):413-21. PubMed ID: 19740399
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: Part I.
    Staatz CE; Goodman LK; Tett SE
    Clin Pharmacokinet; 2010 Mar; 49(3):141-75. PubMed ID: 20170205
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association study of ABCB1 and CYP3A5 gene polymorphisms with sirolimus trough concentration and dose requirements in Chinese renal transplant recipients.
    Miao LY; Huang CR; Hou JQ; Qian MY
    Biopharm Drug Dispos; 2008 Jan; 29(1):1-5. PubMed ID: 17941052
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CYP3A and ABCB1 genetic polymorphisms on the pharmacokinetics and pharmacodynamics of tacrolimus and its metabolites (M-I and M-III).
    Yoon SH; Cho JH; Kwon O; Choi JY; Park SH; Kim YL; Yoon YR; Won DI; Kim CD
    Transplantation; 2013 Mar; 95(6):828-34. PubMed ID: 23364483
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A new functional CYP3A4 intron 6 polymorphism significantly affects tacrolimus pharmacokinetics in kidney transplant recipients.
    Elens L; Bouamar R; Hesselink DA; Haufroid V; van der Heiden IP; van Gelder T; van Schaik RH
    Clin Chem; 2011 Nov; 57(11):1574-83. PubMed ID: 21903774
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of the CYP3A5 genotype on the distributions of dose-adjusted trough concentrations and incidence of rejection in Japanese renal transplant recipients receiving different tacrolimus formulations.
    Niioka T; Kagaya H; Saito M; Inoue T; Numakura K; Yamamoto R; Habuchi T; Satoh S; Miura M
    Clin Exp Nephrol; 2017 Oct; 21(5):787-796. PubMed ID: 28271256
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of CYP3A polymorphisms with the pharmacokinetics of cyclosporine A in early post-renal transplant recipients in China.
    Meng XG; Guo CX; Feng GQ; Zhao YC; Zhou BT; Han JL; Chen X; Shi Y; Shi HY; Yin JY; Peng XD; Pei Q; Zhang W; Wang G; He M; Liu M; Yang JK; Zhou HH
    Acta Pharmacol Sin; 2012 Dec; 33(12):1563-70. PubMed ID: 23085740
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of ABCB1, CYP3A4*18B and CYP3A5*3 genotypes with the pharmacokinetics of tacrolimus in healthy Chinese subjects: a population pharmacokinetic analysis.
    Shi XJ; Geng F; Jiao Z; Cui XY; Qiu XY; Zhong MK
    J Clin Pharm Ther; 2011 Oct; 36(5):614-24. PubMed ID: 21916909
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of CYP3A4-392A/G, CYP3A5-6986A/G, and ABCB1-3435C/T Polymorphisms with Tacrolimus Dose, Serum Concentration, and Biochemical Parameters in Mexican Patients with Kidney Transplant.
    Alatorre-Moreno EV; Saldaña-Cruz AM; Pérez-Guerrero EE; Morán-Moguel MC; Contreras-Haro B; López-de La Mora DA; Dávalos-Rodríguez IP; Marín-Medina A; Rivera-Cameras A; Balderas-Peña LA; Gómez-Ramos JJ; Cortés-Sanabria L; Salazar-Páramo M
    Genes (Basel); 2024 Apr; 15(4):. PubMed ID: 38674430
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of CYP3A5 and ABCB1 gene polymorphisms and other factors on tacrolimus dosing in Caucasian liver and kidney transplant patients.
    Provenzani A; Notarbartolo M; Labbozzetta M; Poma P; Vizzini G; Salis P; Caccamo C; Bertani T; Palazzo U; Polidori P; Gridelli B; D'Alessandro N
    Int J Mol Med; 2011 Dec; 28(6):1093-102. PubMed ID: 21922127
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tacrolimus dose requirements and CYP3A5 genotype and the development of calcineurin inhibitor-associated nephrotoxicity in renal allograft recipients.
    Kuypers DR; Naesens M; de Jonge H; Lerut E; Verbeke K; Vanrenterghem Y
    Ther Drug Monit; 2010 Aug; 32(4):394-404. PubMed ID: 20526235
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.